Nyse to begin trading Fifth Third Bancorp in historic bank transfer on June 12
Fifth Third Bancorp is moving its primary stock listing from Nasdaq Global Select to the New York Stock Exchange, effective June 12, 2026. This transfer is being touted by the NYSE as the largest bank transfer in its 234-year history. The move highlights the NYSE's continued pursuit of prominent companies, even amidst a day filled with other significant market activities and geopolitical developments.
Siemens named PLM leader in Gartner report
Siemens has been recognized as a Leader in Gartner's Magic Quadrant for PLM Software in Discrete Manufacturing Industries. This recognition highlights Siemens' Teamcenter software, particularly its embedded AI, BOM enhancements, and the success of its cloud SaaS offering, Teamcenter X. Gartner defines Leaders as companies that execute well on their current vision and are well-positioned for the future.
Fifth Third Bancorp to Begin Trading on NYSE After Transfer from NASDAQ
Fifth Third Bancorp is transferring its publicly traded securities from Nasdaq to the New York Stock Exchange, with its common stock retaining the ticker symbol FITB and expected to begin trading on the NYSE on June 12. This move follows the Cincinnati-based bank's acquisition of Comerica Bank and plans for a Texas headquarters in Dallas. The article also covers American Airlines' new gates at DFW Airport and Canyon Partners' launch of Canyon ABF Partners.
CLMT SEC Filings - Calumet 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Calumet (CLMT) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It details recent filings such as The Heritage Group's amended 13D filing showing changes in beneficial ownership and gifts of shares, as well as multiple Form 4 filings regarding equity awards (Restricted Stock Units) to Calumet directors. The platform also offers AI-generated summaries, impact scoring, and sentiment analysis for each filing.
Metlife Preferreds Update: Series A Drops From Hold To Sell; Others Stay Holds (MET.PR.A)
MetLife offers three exchange-traded preferred stocks (Series A, E, and F) for portfolio diversification, all BBB-rated, non-cumulative, and tax-advantaged. While Series E and F are rated as "Holds" due to their call hierarchy and yield dynamics, Series A has been downgraded to a "Sell" due to its significantly lower yield compared to the others. The author suggests Series A's floating rate offers better price support in rising interest rate environments, yet its current yield underperformance warrants the changed rating.
Danaher Corporation $DHR Shares Sold by UniSuper Management Pty Ltd
UniSuper Management Pty Ltd reduced its stake in Danaher Corporation (NYSE:DHR) by 5.6% during the fourth quarter, selling 9,619 shares. Despite this, other institutional investors increased their holdings. Danaher reported strong Q1 earnings, beating analyst estimates, and announced a quarterly dividend of $0.40 per share, contributing to a "Moderate Buy" consensus rating from analysts with an average price target of $233.61.
Smucker experiences cat food growth, offsetting dog snacks decline in Q4
The J.M. Smucker Company reported strong cat food growth in Q4 fiscal year 2026, driven by Meow Mix, which helped offset a decline in dog snacks, particularly Milk-Bone. While dog snack sales faced softness, the company plans strategic initiatives, including product innovation and e-commerce expansion, to reaccelerate growth across both pet food segments. Overall, the company delivered positive net sales and earnings growth and provided guidance for fiscal year 2027.
AbbVie reports nine-year CLL14 trial data for Venclexta at EHA 2026
AbbVie announced long-term follow-up results from its Phase 3 CLL14 clinical trial at EHA 2026, demonstrating the durable efficacy of Venclexta (venetoclax) as a fixed-duration therapy for previously untreated chronic lymphocytic leukemia (CLL) patients. The nine-year data showed a median progression-free survival of 6.4 years and a median time to next treatment of 7.6 years for patients treated with Venclexta plus obinutuzumab, affirming its role in frontline CLL care. The safety profile remained consistent, highlighting predictable disease control without continuous long-term dosing.
SpaceX’s IPO Frenzy Just Spawned a New Risk That Could Cost Investors a Fortune
SpaceX's record-setting $75 billion IPO has led to an explosion in leveraged ETFs designed to amplify its daily returns, such as the ProShares Ultra SpaceX ETF (SPCF). While these funds promise magnified gains, they reset daily, making them unsuitable for long-term investors due to daily compounding and volatility drag, which can lead to losses even if SpaceX stock moves as predicted over longer periods. Investors are warned to stick to SpaceX stock itself or index funds for exposure, as leveraged ETFs are built for short-term traders, not wealth accumulation.
BRAEMAR HOTELS & RESORTS ANNOUNCES CONCLUSION OF STRATEGIC REVIEW PROCESS AND PLAN TO BECOME A SELF-MANAGED REIT AND REMAIN PUBLICLY TRADED
Braemar Hotels & Resorts (NYSE: BHR) announced a strategic plan to become a self-managed REIT, concluding a lengthy review process. This move involves terminating its advisory agreement with Ashford, reconstituting its Board with new independent directors, and directly hiring its management team, which is expected to save over $25 million annually in G&A costs. The company aims to simplify its corporate structure, improve governance, and enhance shareholder value, while maintaining a portfolio of 6-8 luxury properties.



